Allergan Adds Device To Glaucoma Portfolio
This article was originally published in The Gray Sheet
Executive Summary
The pharmaceutical firm is entering the highly touted micro-invasive glaucoma surgery space with an acquisition of AqueSys, adding a device to its established portfolio of glaucoma drugs.
You may also be interested in...
FDA Leaps To Draft Glaucoma Device Guidance
FDA issued a "leap frog" draft guidance for minimally invasive glaucoma surgery (MIGS) devices based on strong interest in the nascent field from manufacturers. The recommendations under the guidance reflect discussion during a 2014 stakeholder workshop.
Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker